Investment analysts at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 12-month low of $0.00 and a 12-month high of $0.00.
About Genocea Biosciences
Read More
- Five stocks we like better than Genocea Biosciences
- What Are Growth Stocks and Investing in Them
- The Charles Schwab Company Can Hit New Highs
- What Are Dividend Contenders? Investing in Dividend Contenders
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- What is the NASDAQ Stock Exchange?
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.